Evidence map›Paper›PMID 39239645›Full record

ReviewFrontiers in pharmacology2024

Pharmacological profile of dicaffeoylquinic acids and their role in the treatment of respiratory diseases.

Matthias Hufnagel, André Rademaekers, Anika Weisert, Hanns Häberlein, Sebastian Franken

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Oral Administration ofAnimals : an open access journal from MDPI · 2026
    Article
  2. Process Optimization ofAntioxidants (Basel, Switzerland) · 2026
    Article
  3. Aspen PlusAntioxidants (Basel, Switzerland) · 2026
    Article
  4. Exploring the Aerial Parts ofPlants (Basel, Switzerland) · 2026
    Article
  5. Antiparasitic Activity ofVeterinary sciences · 2026
    Article
  6. Article
  7. Article
  8. Nephroprotective Effects ofCurrent issues in molecular biology · 2025
    Article
  9. Article
  10. Evaluating the Anti-Inflammatory and Chondroprotective Effects ofInternational journal of molecular sciences · 2025
    Article
  11. Frontiers in pharmacology · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matthias HufnagelEngelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany.
André RademaekersEngelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany.
Anika WeisertEngelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany.
Hanns HäberleinMedical Faculty, Institute of Biochemistry and Molecular Biology, University of Bonn, Bonn, Germany.
Sebastian FrankenMedical Faculty, Institute of Biochemistry and Molecular Biology, University of Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dicaffeoylquinic acids (DCQAs) are polyphenolic compounds found in various medicinal plants such as

Indexed as

DCQAdicaffeoylquinic acidisochlorogenic acidpharmacological profilepre-clinical evaluationrespiratory disease

Identifiers

PMID39239645
PMCPMC11374715

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.